Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma.

被引：1

作者：

Slingluff, Craig L.

Blumenstein, Brent A.

Lewis, Karl D.

Andtbacka, Robert Hans Ingemar

Hyngstrom, John Robert

Milhem, Mohammed M.

Markovic, Svetomir

Hamid, Omid

Hernandez-Aya, Leonel Fernando

Bowles, Tawnya Lynn

Philips, Prejesh

Jang, Sekwon

Lutzky, Jose

Bar, Anna

Beitsch, Peter D.

机构：

[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

[2] Trial Architecture Consulting, Washington, DC USA

[3] Univ Colorado Denver, Sch Med, Aurora, CO USA

[4] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[5] Univ Utah, Salt Lake City, UT USA

[6] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA

[7] Mayo Clin, Rochester, MN USA

[8] Angeles Clin & Res Inst, Los Angeles, CA USA

[9] Univ Michigain Hlth Syst, Ann Arbor, MI USA

[10] Intermt Med Ctr, Murray, UT USA

[11] Univ Louisville, Louisville, KY 40292 USA

[12] Inova Schar Canc Inst, Fairfax, VA USA

[13] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA

[14] OHSU Knight Canc Inst, Portland, OR USA

[15] Dallas Surg Grp, Dallas, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10017

引用

页数：2

共 50 条

[1] A multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in post-resection melanoma patients at high risk of recurrence
Slingluff, Craig
Blumenstein, Brent
Lewis, Karl
Andtbacka, Robert
Hyngstrom, John
Milhem, Mohammed
Markovic, Svetomir
Hamid, Omid
Hernandez-Aya, Leonel
Bowles, Tawnya
Philips, Prejesh
Claveau, Joel
Jang, Sekwon
Lutzky, Jose
Bar, Anna
Beitsch, Peter
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2] Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff, Craig L.
Lewis, Karl D.
Andtbacka, Robert
Hyngstrom, John
Milhem, Mohammed
Markovic, Svetomir N.
Bowles, Tawnya
Hamid, Omid
Hernandez-Aya, Leonel
Claveau, Joel
Jang, Sekwon
Philips, Prejesh
Holtan, Shernan G.
Shaheen, Montaser F.
Curti, Brendan
Schmidt, William
Butler, Marcus O.
Paramo, Juan
Lutzky, Jose
Padmanabhan, Arvinda
Thomas, Sajeve
Milton, Daniel
Pecora, Andrew
Sato, Takami
Hsueh, Eddy
Badarinath, Suprith
Keech, John
Kalmadi, Sujith
Kumar, Pallavi
Weber, Robert
Levine, Edward
Berger, Adam
Bar, Anna
Beck, J. Thaddeus
Travers, Jeffrey B.
Mihalcioiu, Catalin
Gastman, Brian
Beitsch, Peter
Rapisuwon, Suthee
Glaspy, John
McCarron, Edward C.
Gupta, Vinay
Behl, Deepti
Blumenstein, Brent
Peterkin, Joanna J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
[3] Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma
Curiel-Lewandrowski, Clara
Swetter, Susan M.
Einspahr, Janine G.
Hsu, Chiu-Hsieh
Nagle, Ray
Sagerman, Paul
Tangrea, Joseph
Parnes, Howard
Alberts, David S.
Chow, Hsiao-Hui
CANCER, 2012, 118 (23) : 5848 - 5856
[4] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Cui, Chuanliang
Mao, Lili
Chi, Zhihong
Si, Lu
Sheng, Xinan
Kong, Yan
Li, Siming
Lian, Bin
Gu, Kangsheng
Tao, Min
Song, Xin
Lin, Tongyu
Ren, Xiubao
Qin, Shukui
Guo, Jun
MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
[5] Efficacy of mirtazapine for prevention of depressive relapse: A placebo-controlled double-blind trial of recently remitted high-risk patients
Thase, ME
Nierenberg, AA
Keller, MB
Panagides, J
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (10) : 782 - 788
[6] A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF FISH-OIL IN HIGH-RISK PREGNANCY
ONWUDE, JL
LILFORD, JR
HJARTARDOTTIR, H
STAINES, A
TUFFNELL, D
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1995, 102 (02): : 95 - 100
[7] Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Brighton, Timothy A.
Khot, Amit
Harrison, Simon J.
Ghez, David
Weiss, Brendan M.
Kirsch, Andres
Magen, Hila
Gironella, Mercedes
Oriol, Albert
Streetly, Matthew
Kranenburg, Britte
Qin, Xiang
Bandekar, Rajesh
Hu, Peter
Guilfoyle, Mary
Qi, Ming
Nemat, Sepideh
Goldschmidt, Hartmut
CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3772 - 3775
[8] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Hoos, Axel
de Pril, Veerle
Gurunath, Ravichandra Karra
de Schaetzen, Gaetan
Suciu, Stefan
Testori, Alessandro
LANCET ONCOLOGY, 2015, 16 (05): : 522 - 530
[9] Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2021, 32 : S1314 - S1315
[10] Azithromycin in high-risk, refractory chronic rhinosinusitus after endoscopic sinus surgery and corticosteroid irrigations: a double-blind, randomized, placebo-controlled trial
Maniakas, Anastasios
Asmar, Marc-Henri
Renteria, Axel Eluid
Nayan, Smriti
Alromaih, Saud
Endam, Leandra Mfuna
Sampalis, John Sam
Desrosiers, Martin
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2021, 11 (04) : 747 - 754

← 1 2 3 4 5 →